


# NEW - THE REBOOT STUDY

NSU IRB APPROVED:  
Approved: August 11, 2021  
Expired: August 10, 2022  
IRB#: 2019-359

## Reboot Study Overview

Mifepristone/Etanercept Combination Therapy




The Gulf War Illness Clinical Trials and Interventions Center (GWICTIC) is excited to present their newest study, the Reboot Study. This study was designed with you in mind! This combination therapy study takes place over 24 weeks - 7 in-person visits and 2 virtual/phone visits - at either Nova Southeastern University's Davie Campus or the Miami Veterans Affairs Healthcare System. GWICTIC is currently enrolling male Gulf War Veterans with Gulf War Illness symptoms.

\*Treatment time lasts for 14 weeks, with 10 weeks of follow ups, for a total of 24 weeks.

The Reboot Study lasts 24 weeks (14 weeks - treatment time & 10 weeks - follow ups) from enrollment to completion. When enrollment begins, volunteers will be given Etanercept once weekly for 12 weeks via injection. Participants can self-administer weekly shots after training or come into the clinic to receive the weekly injection. After 12 weeks, volunteers will be dispensed mifepristone, an oral medication. Mifepristone will be taken once daily for a period of one week at either 300 mg or 600 mg, with participants randomized between the two dosing arms.

## Reboot Study - Timeline

Mifepristone/Etanercept Combination Therapy



[Etanercept is a tumor necrosis factor (TNF) blocker and is FDA-approved at approved doses. Mifepristone is a progesterone blocker and is FDA-approved at approved doses.]

To learn more visit: <http://bit.ly/AboutReboot>.

**If you are interested in participating or have any questions, please email: [gwictic@nova.edu](mailto:gwictic@nova.edu) or call: 954-262-2870.**